Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Nonalcoholic Fatty Liver
Weight, Energy, Lipids, and the Liver (WELL) Study
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy…
- Trial name
- NCT05199948
- Testing
- Soybean Oil Foods, Palm Oil Foods
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Ohio State University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 118 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes, Prediabetes
Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk
Vegetarian diets have been associated with a reduced risk of preventable diseases such as type 2 diabetes and cardiovascular disease. These effects may be mediated through direct or indirect pathways.
- Conditions
- Diabetes, Prediabetes, Metabolic Syndrome, Dysglycemia
- Trial name
- NCT02037321
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- John Sievenpiper
Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH
This single arm interventional cohort study is designed to explore the feasibility of using BT-NCBT-00x to improve liver fat, inflammation, and stiffness in patients diagnosed with NAFLD or NASH over a 3 month intervention.
- Conditions
- Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
- Trial name
- NCT05357248
- Testing
- BT-NCBT-00X
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Better Therapeutics
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Evaluate the Effectiveness of Legalon®
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
- Trial name
- NCT05051527
- Testing
- Legalon® 140 mg
- Where
- Thailand
- Volunteers
- 362 people
- Sponsor
- Mylan Inc.
Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and…
- Conditions
- Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease, Hypertension, Dyslipidaemia
- Trial name
- OneSTOP (NCT06890169)
- Testing
- OneSTOP program, Standard of care weight management program
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
Non Alcoholic Steatohepatitis
The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study
To study the effects of Hesperidin, flaxseed and both together on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 100 patients who referred to…
- Trial name
- NCT03734510
- Testing
- Dietary Supplement: hesperidin and flaxseed, Dietary Supplement: hesperidin, Dietary Supplement: flaxseed
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- National Nutrition and Food Technology Institute
Nonalcoholic Steatohepatitis
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
- Trial name
- NCT04583423
- Testing
- MK-3655
- Where
- 180 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
Approximately 90% of people undergoing bariatric surgery have NAFLD, which is a condition where fat accumulates in the liver and can lead to inflammation and scarring.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- EDISON (NCT03186859)
- Testing
- Roux-en-Y Gastric Bypass (RYGB) surgery, Sleeve Gastrectomy (SG) surgery
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
- Trial name
- CENTRICITY (NCT05623189)
- Testing
- HTD1801
- Where
- 45 sites in United States, Hong Kong and 1 more
- Volunteers
- 218 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice.
- Trial name
- NCT02815891
- Where
- 72 sites in United States, Germany and 1 more
- Volunteers
- 7,330 people
- Sponsor
- Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.
- Trial name
- NCT03950882
- Testing
- PXL770
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Poxel SA
NAFLD, NASH
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT06410924
- Testing
- DD01
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuraly, Inc.
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
CKD, NAFLD
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut
The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question[s] it aims to answer are: [question 1] prevalence of NAFLD in CKD patients.
- Trial name
- NCT06009250
- Volunteers
- 200 people
- Sponsor
- Muhammad Ameen Abdelrady Abdelaziz
Non-alcoholic Fatty Liver Disease
Exercise and Cerebral Hemodynamics in MAFLD.
Arterial stiffness and endothelial dysfunction present in metabolic associated fatty liver disease (MAFLD) confer increased cardiovascular risk, which represents the leading cause of mortality in this group of patients.
- Trial name
- CERHEMAFLD (NCT05520697)
- Testing
- Nutritional intervention, Mental exercise., Physical training.
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Nonalcoholic Steatohepatitis, Type 2 Diabetes Mellitus
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT02769091)
- Testing
- TEV-45478
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Nonalcoholic Steatohepatitis (NASH)
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT04616014
- Testing
- ORMD-0801 QD
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Oramed, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.